David Rubenstein Joins Moderna's Board of Directors

Moderna, Inc. (NASDAQ:MRNA) announced that David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, will join its Board of Directors effective August 5, 2024. Rubenstein will replace retiring director Stephen Berenson and join the Audit Committee. Co-founder Robert Langer will also retire but will continue providing advisory services.

Noubar Afeyan, Chairman of Moderna, emphasized Rubenstein's extensive experience in global policy and investment. Rubenstein expressed his honor in joining Moderna, focusing on the company's commitment to medical innovation and global health challenges. CEO Stéphane Bancel echoed the enthusiasm for Rubenstein's strategic guidance.

Afeyan praised Langer and Berenson for their significant contributions. Langer noted it was the right time to step down, reflecting on the company's progress. Berenson expressed pride in Moderna's achievements since he joined seven years ago. Moderna's Nominating and Corporate Governance Committee will seek new directors with scientific expertise.